Rare diseases

News

bluebird bio to split into oncology and gene therapy special...

US biotech bluebird bio has announced plans to split into two this year, with a separate oncology business spinning off as the company prepares to bring its products to market.

Views & Analysis

2020 review - Pharma’s progress outside of COVID-19

2020 in review: Pharma’s progress outside of COVID-19

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies.

R&D

Tay-Sachs and rare disease registries – the Health Heroes po...

Episode four of Kantar Health’s Health Heroes podcast tackles pharma’s rare disease challenges, the role of patient registries and hears a moving story about the rare genetic disorder Tay-S

Events